Bartter syndrome medical therapy: Difference between revisions
TayyabaAli (talk | contribs) No edit summary |
TayyabaAli (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
Main article: [[Bartter syndrome|Bartter syndrome]] | |||
{{Bartter syndrome}} | {{Bartter syndrome}} | ||
{{CMG}}{{AE}}{{TAM}} | {{CMG}}{{AE}}{{TAM}} | ||
Revision as of 19:54, 30 July 2020
Main article: Bartter syndrome
|
Bartter syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bartter syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Bartter syndrome medical therapy |
|
Risk calculators and risk factors for Bartter syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]
Overview
Medical Therapy
- Prostaglandin synthetase inhibitors suppress the production of prostaglandin. This corrects all the chemical features of the syndrome except the urinary loss of potassium.[1]
While patients should be encouraged to include liberal amounts of sodium and potassium in their diet, potassium supplements are usually required, and spironolactone is also used to reduce potassium loss. Nonsteroidal antiinflammatory drugs (NSAIDs) can be used as well, and are particularly helpful in patients with neonatal Bartter's syndrome. Angiotensin-converting enzyme (ACE) inhibitors can also be used.
References
- ↑ Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW; et al. (1976). "Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis". Am J Med. 61 (1): 43–51. doi:10.1016/0002-9343(76)90029-2. PMID 820194.